Nanobodies Market Regional
Analysis
Europe is expected to hold
dominant position in global Nanobodies
Market, owing to the first mover advantage. Marketing authorization application
(MMA) to EMA for Caplacizumab was filed by Ablynx in February 2017, and the
company expects to get approval in 2018. If approved, Europe will be the only
market to have nanobodies commercially available. However, North America is
expected to show rapid growth in this market, as the company is planning to
file for biologic license agreement for the same product to U.S. FDA in 2018,
and expects to get approval from FDA by 2019. Once approved in U.S., the
company may plan to reap the maximum benefit out of it. Furthermore, the drug,
Caplacizumab, is expected to have better efficiency compared to both the
available treatment (i.e. plasma exchange therapy and immunosuppressant) for
the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). In Asia
Pacific, Japan may take the lead as multiple products such as Caplacizumab,
Vobarilizumab, and ALX- 0171 has successfully gone through initial phase of
clinical development.
Nanobodies are considered to be
one of the best technology in the fields of research, diagnostics and therapy
especially in cancer research. These technology was developed from antigen
binding fragments, originating from Camelid heavy-chain antibodies. These
molecules do not have light chains, which is an essential part of antibody
found in humans. Based on the above finding, nanobodies molecule containing
single-domain only were developed, and these molecules contain functional and
structural properties similar to heavy chain antibodies.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1680
These molecules have several
advantages as compared to the conventional antibodies such as small-size, nano
to picomolar affinities, and multiple route of administration. Ablynx, which is
acquired by Sanofi S.A., is one of the leading company in this market.
Nanobodies Market Drivers
Currently, no products are
available in the market, but there are multiple products in the pipeline
including few in very late stage of clinical trials. For instance, marketing authorization
application for Caplacizumab for the treatment of acquired thrombotic
thrombocytopenic purpura (aTTP) has been submitted to European Medicine Agency
(EMA) in February 2017. The product, Caplacizumab, is expected to be launched
in Europe in 2018. Moreover, the company, Ablynx, is expected to file for
biologic license agreement to the U.S. Food and Drug Administration (FDA) in
2018, and is expected to launch this product in U.S. in 2019. Both, Europe and
U.S. are the key markets for any biologics including monoclonal antibodies and
are expected to be the high revenue generating market for nanobodies. Hence,
approval by regulatory bodies in Europe and U.S. to Caplacizumab in very near
future (i.e. 2018, 2019) is expected to drive the growth of global nanobodies
market. As per the company, Ablynx, estimates the product has potential to
generate more than US$ 1 Bn. Furthermore, there are multiple products in early
stage of clinical development i.e. preclinical, phase 0, and phase 1. Ablynx
alone had 8 products in clinical development phase (i.e. phase 0 to phase 3)
and overall 45 products in pipeline as of March 2017.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/nanobodies-market-1680
Lucrative potential in the market
has motivated leading biotechnology companies such as C.H. Boehringer Sohn AG
& Ko. KG, MERCK KGaA, Merck & Co., Inc., AbbVie, Inc., Novo Nordisk A/S
and Sanofi S.A. to collaborate or enter into a partnership agreement with the
nanobodies manufacturer, Ablynx. In July 2017, Ablynx entered into a research
collaboration and licensing agreement with Sanofi S.A. for the treatment of
various immune-mediated inflammatory diseases. As per the agreement, Sanofi
S.A. will get access to Ablynx’s scientists and technology platforms, and also,
to certain drugs in pipeline. Furthermore, in 2015, Ablynx and Merck & Co.,
Inc. expanded their collaboration agreement focused on immuno-oncology. In
January 2018, Sanofi S.A. made an offer to acquire Ablynx, and the offer was
unanimously recommended by Ablynx board.
Nanobodies Market Restraint
Presently, there are no products
in market, and more than two-third products in very early phase of development,
and these products have to go through various phases of clinical development.
Failure in clinical trials for these products or slow approval by the
regulatory bodies in the market may prove to be vital restraint in this market.
Nanobodies Market Key Players
Ablynx (now part of Sanofi S. A.)
is the key player in the global nanobodies market. Moreover, the company is
developing various products with leading biology companies such as Novo Nordisk
A/S, Merck & Co., Inc., Merck KGaA, AbbVie, Inc., and C.H. Boehringer Sohn
AG & Ko. KG.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1680
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200 Seattle,
WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment